LANDMARK ANALYSES IN THE PIVOTAL PONATINIB PACE TRIAL: IMPACT OF EARLY RESPONSES ON 3-YEAR OUTCOMES IN HEAVILY PRETREATED CP-CML PATIENTS

被引：0
|
作者：
Mueller, M. [1 ]
Baccarani, M. [2 ]
Deininger, M. W. [3 ]
Guilhot, F. [4 ]
Hochhaus, A. [5 ]
Hughes, T. P. [6 ,7 ]
Shah, N. P. [8 ]
Talpaz, M. [9 ]
Lustgarten, S. [10 ]
Rivera, V. M. [10 ]
Clackson, T. [10 ]
Haluska, F. G. [10 ]
Cortes, J. E. [11 ]
机构：
[1] Univ Med Mannheim, Mannheim, Germany
[2] S Orsola Malpighi Univ Hosp, Bologna, Italy
[3] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[4] CHU Poitiers, Inserm CIC 1402, Poitiers, France
[5] Jena Univ Hosp, Jena, Germany
[6] South Australian Hlth & Med Res Inst, Adelaide, SA, Australia
[7] Univ Adelaide, Adelaide, SA, Australia
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
[9] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[10] ARIAD Pharmaceut Inc, Cambridge, MA USA
[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P615
引用
收藏
页码：239 / 239
页数：1
相关论文
共 43 条
  • [31] SURVIVAL OUTCOMES IN PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) RECEIVING THIRD-OR SUBSEQUENT LINE (3L) TREATMENT PRIOR TO THE AVAILABILITY OF PONATINIB
    Stellato, D.
    McGarry, L.
    Huang, H.
    Hastings, S.
    Delea, T.
    HAEMATOLOGICA, 2017, 102 : 434 - 434
  • [32] Survival outcomes in patients with chronic phase chronic myeloid leukemia (CP-CML) receiving third- or subsequent line (3L) treatment prior to the availability of ponatinib.
    Stellato, Daniel R.
    McGarry, Lisa
    Huang, Hui
    Hastings, Shaina
    Delea, Thomas E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic
    Kantarjian, Hagop M.
    Deininger, Michael W.
    Abruzzese, Elisabetta
    Apperley, Jane
    Cortes, Jorge E.
    Chuah, Charles
    DeAngelo, Daniel J.
    DiPersio, John F.
    Hochhaus, Andreas
    Lipton, Jeffrey H.
    Nicolini, Franck E.
    Ibarz, Javier Pinilla
    Rea, Delphine
    Rosti, Gianantonio
    Rousselot, Philippe
    Shah, Neil P.
    Talpaz, Moshe
    Srivastava, Shouryadeep
    Lu, Vickie
    Mauro, Michael J.
    BLOOD, 2020, 136
  • [34] Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Treatment-Resistant Patients with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Treated with Ponatinib from the Phase 2 Optic Trial
    Apperley, Jane F.
    Cortes, Jorge E.
    Jabbour, Elias
    Hochhaus, Andreas
    Hughes, Timothy
    Chuah, Charles
    de Lavallade, Hugues
    Deininger, Michael W.
    Lipton, Jeffrey H.
    Lomaia, Elza
    Maness, Lori
    Mauro, Michael
    McCloskey, James
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rojas, Christine
    Rousselot, Philippe
    Sacha, Tomasz
    Talpaz, Moshe
    Turkina, Anna
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Rosti, Gianantonio
    BLOOD, 2022, 140 : 6760 - 6762
  • [35] Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial
    Apperley, Jane
    Cortes, Jorge
    Jabbour, Elias
    Hochhaus, Andreas
    Hughes, Timothy
    Chuah, Charles
    de Lavallade, Hugues
    Deininger, Michael
    Lipton, Jeffrey H.
    Lomaia, Elza
    Maness, Lori
    Mauro, Michael
    McCloskey, James
    Moiraghi, Beatriz
    Pavlovsky, Carolina
    Rojas, Christine
    Rousselot, Philippe
    Sacha, Tomasz
    Talpaz, Moshe
    Turkina, Anna
    Sutton, Maria Undurraga
    Ren, Xiaowei
    Vorog, Alexander
    Rosti, Gianantonio
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S339 - S339
  • [36] The early risers longitudinal prevention trial: Examination of 3-year outcomes in aggressive children with intent-to-treat and as-intended analyses
    August, GJ
    Hektner, JM
    Egan, EA
    Realmuto, GM
    Bloomquist, ML
    PSYCHOLOGY OF ADDICTIVE BEHAVIORS, 2002, 16 (04) : S27 - S39
  • [37] Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
    Saglio, Giuseppe
    Kantarjian, Hagop M.
    Shah, Neil
    Jabbour, Elias J.
    Quintas-Cardama, Alfonso
    Luis Steegmann, Juan
    Boque, Concepcion
    Chuah, Charles
    Pavlovsky, Carolina
    Mayer, Jiri
    Ukropec, Jon
    Wildgust, Mark
    Hochhaus, Andreas
    BLOOD, 2012, 120 (21)
  • [38] Impact of fixed or flexible abobotulinumtoxinA injection intervals on patient outcomes: Analyses from a 3-year observational study following patients with cervical dystonia
    Colosimo, C.
    Chung, T.
    Charles, D.
    Misra, V.
    Om, S.
    Maisonobe, P.
    MOVEMENT DISORDERS, 2019, 34
  • [39] THE IMPACT OF EARLY MOLECULAR RESPONSE ON LONG-TERM OUTCOMES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) TREATED WITH DASATINIB OR IMATINIB FROM THE DASISION TRIAL
    Stegelmann, F.
    Shah, N. P.
    Saglio, G.
    Hochhaus, A.
    Bilmes, R.
    Li, L.
    Cortes, J. E.
    HAEMATOLOGICA, 2016, 101 : 240 - 240
  • [40] Impact of early molecular response to nilotinib (NIL) or imatinib (IM) on the long-term outcomes of newly diagnosed patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP): Landmark analysis of 4-year (y) data from ENESTnd
    Saglio, Giuseppe
    Hughes, Timothy P.
    Larson, Richard A.
    Issaragrilsil, Surapol
    Turkina, Anna G.
    Steegmann, Juan Luis
    Lopez, Jose L.
    Nakaseko, Chiaki
    Kalaycio, Matt E.
    Huguet, Francoise
    Kemp, Charisse N.
    Fan, Xiaolin
    Menssen, Hans D.
    Kantarjian, Hagop M.
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345